Related Experiment Video
Updated: May 15, 2026
07:32
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Janus PEG-based dendrimers for use in combination therapy: controlled multi-drug loading and sequential release
Aaron L Acton1, Cristina Fante, Brian Flatley
1Department of Chemistry, Reading School of Pharmacy, University of Reading, Whiteknights, Reading, United Kingdom.
Biomacromolecules
|January 12, 2013
Summary
Novel Janus dendrimers offer a promising drug delivery system for combination therapy. These PEG-based nanostructures enable sequential release of multiple drugs, showing no toxicity to cells or red blood cells.
Area of Science:
- Polymer Chemistry
- Nanotechnology
- Drug Delivery
Background:
- Combination therapy is increasingly vital for treating complex diseases like cancer.
- Existing drug delivery systems struggle to effectively deliver multiple therapeutic agents simultaneously.
- Developing advanced nanocarriers is crucial for enhancing combination therapy efficacy.
Purpose of the Study:
- To synthesize and characterize novel Janus dendrimers for combination drug delivery.
- To investigate the differential release kinetics of two model drugs from the dendrimers.
- To evaluate the safety and biocompatibility of the developed Janus dendrimers.
Main Methods:
- Synthesis of first and second-generation PEG-based dendrons.
- Attachment of benzyl alcohol (BA) and 3-phenylpropionic acid (PPA) via distinct linkers.
- Coupling of dendrons using (3 + 2) cycloaddition to form Janus dendrimers.
- In vitro release studies in plasma and cytotoxicity assays (HUVEC, hemolysis).
Main Results:
- Four Janus dendrimers with varying ratios of BA and PPA were successfully synthesized.
- Sequential drug release was observed, with BA releasing faster than PPA.
- Dendrimers delivered precise molecular ratios and increasing amounts of the model drugs.
- The dendrimers demonstrated noncytotoxicity and no hemolysis, indicating good biocompatibility.
Conclusions:
- Janus PEG-based dendrimers are effective nanocarriers for combination therapy.
- Differential drug release kinetics can be controlled by linker chemistry and dendrimer generation.
- These novel dendrimers present a safe and versatile platform for delivering multiple therapeutic agents.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...